Evidence map›Paper›PMID 27460677›Full record

ArticleInternational journal of hematology2016

Phase I dose escalation study of high dose carfilzomib monotherapy for Japanese patients with relapsed or refractory multiple myeloma.

Shinsuke Iida, Kensei Tobinai, Masafumi Taniwaki, Yoshihisa Shumiya, Toru Nakamura, Takaaki Chou

Abstract readClinical Trial, Phase IMulticenter Study
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shinsuke IidaDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. iida@med.nagoya-cu.ac.jp.
Kensei TobinaiDepartment of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Masafumi TaniwakiDivision of Hematology and Oncology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Yoshihisa ShumiyaDepartment of Oncology Clinical Development Planning, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
Toru NakamuraDepartment of Oncology Clinical Development Planning, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
Takaaki ChouDepartment of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a multicenter, open-label Phase I study of single-agent carfilzomib in Japanese patients with relapsed or refractory multiple myeloma. The primary endpoints were tolerability and safety. Carfilzomib was administrated for 30 min on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. In cycle 1, doses for days 1 and 2 were 20 mg/m CLINICAL

trial registrationJapicCTI-122020.

Indexed as

Asian PeopleDexamethasoneDose-Response Relationship, DrugDrug Administration ScheduleFeverHumansHypertensionMaximum Tolerated DoseMultiple MyelomaNauseaOligopeptidesRecurrenceVomitingcarfilzomibDexamethasoneOligopeptidesCarfilzomibDose escalationJapanese patientsPhase I studyRelapsed or refractory multiple myeloma

Identifiers

PMID27460677

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.